Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.

Expert Opinion on Therapeutic Patents
Justin J BaileyRalf Schirrmacher

Abstract

Introduction: Tropomyosin receptor kinases (Trks) control processes in the fields of growth, survival, and differentiation of neuronal processes. They also play a crucial role in neurodegenerative diseases as well as different types of cancer. Interest in developing Trk inhibitors to target NTRK fusion-driven cancers has escalated in the last decade, leading to the FDA approval of the pan-Trk inhibitors entrectinib and larotrectinib. The development of next-generation inhibitors that overcome resistance mutations arising from treatment with these first generation inhibitors has been the focus in recent years.Area covered: In this updated patent review for 2016-2019, patents covering inhibitors targeting the Trk family are discussed as a continuation of the previous reviews, Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Parts 1 & 2. The status of Trk inhibitors in clinical trials is also evaluated. For the identification of relevant patents and clinical trials, Web of Science, Google, Google Patents, and patent referencing were used.Expert opinion: The FDA approval of larotrectinib and entrectinib is a prime example of how basket clinical trial design targeting oncogenic drivers, regardless of ...Continue Reading

References

Aug 25, 2001·Annual Review of Neuroscience·E J Huang, L F Reichardt
Nov 4, 2009·Molecular and Cellular Endocrinology·A GrecoM A Pierotti
Mar 16, 2011·Diagnostic Pathology·Johanna M KralikGerald Webersinke
May 24, 2011·Anesthesiology·Patrick W MantyhDavid L Shelton
Jun 2, 2012·Current Neuropharmacology·Dario SiniscalcoVito de Novellis
May 15, 2013·International Journal of Molecular Sciences·Vivek K GuptaStuart L Graham
Jun 4, 2013·The New England Journal of Medicine·Mark M AwadAlice T Shaw
Aug 7, 2013·Nature Genetics·Veronique FrattiniAntonio Iavarone
Oct 29, 2013·Nature Medicine·Aria VaishnaviRobert C Doebele
Sep 11, 2014·Nature Communications·Nicolas StranskyChristoph Lengauer
Dec 21, 2014·Cancer Discovery·Aria VaishnaviRobert C Doebele
Mar 4, 2015·Proceedings of the National Academy of Sciences of the United States of America·Helen Y ZouValeria R Fantin
Nov 8, 2015·Cancer Discovery·Mariangela RussoAlberto Bardelli
Mar 9, 2017·Expert Opinion on Therapeutic Patents·Justin J BaileyVadim Bernard-Gauthier
Mar 9, 2017·Expert Opinion on Therapeutic Patents·Justin J BaileyVadim Bernard-Gauthier
Feb 22, 2018·The New England Journal of Medicine·Alexander DrilonDavid M Hyman
Apr 7, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B Walter
Apr 20, 2018·Journal of Medicinal Chemistry·Sharan K BagalJoseph S Warmus
May 11, 2018·Journal of Medicinal Chemistry·Samo TurkSimone Fulle
Jun 9, 2018·Journal of Hematology & Oncology·Yu Chen, Ping Chi
Sep 23, 2018·Molecular Cancer Therapeutics·Hiroshi TanakaToshiyuki Mio

❮ Previous
Next ❯

Citations

Dec 18, 2020·Frontiers in Oncology·Yuekun WangWenbin Ma
Mar 2, 2021·Acta Pharmaceutica Sinica. B·Tingting JiangLiang Ouyang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Related Papers

Expert Opinion on Therapeutic Patents
Clive McCarthy, Edward Walker
Expert Opinion on Therapeutic Patents
Justin J BaileyVadim Bernard-Gauthier
Expert Opinion on Therapeutic Patents
Justin J BaileyVadim Bernard-Gauthier
Expert Opinion on Therapeutic Patents
Tao WangMichelle L Lamb
© 2021 Meta ULC. All rights reserved